836 related articles for article (PubMed ID: 16421599)
41. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
42. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
43. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
44. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
45. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
46. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
Kuroda T; Martuza RL; Todo T; Rabkin SD
BMC Biotechnol; 2006 Sep; 6():40. PubMed ID: 16995942
[TBL] [Abstract][Full Text] [Related]
47. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
48. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
[TBL] [Abstract][Full Text] [Related]
49. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
50. Medical application of herpes simplex virus.
Watanabe D
J Dermatol Sci; 2010 Feb; 57(2):75-82. PubMed ID: 19939634
[TBL] [Abstract][Full Text] [Related]
51. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
[TBL] [Abstract][Full Text] [Related]
52. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
53. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
[TBL] [Abstract][Full Text] [Related]
54. Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase.
Logvinoff C; Epstein AL
Virology; 2000 Feb; 267(1):102-10. PubMed ID: 10648187
[TBL] [Abstract][Full Text] [Related]
55. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
56. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
57. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms.
Derubertis BG; Stiles BM; Bhargava A; Gusani NJ; Hezel M; D'Angelica M; Fong Y
Cancer Gene Ther; 2007 Jun; 14(6):590-7. PubMed ID: 17431402
[TBL] [Abstract][Full Text] [Related]
58. Replication-competent herpes simplex vectors: design and applications.
Argnani R; Lufino M; Manservigi M; Manservigi R
Gene Ther; 2005 Oct; 12 Suppl 1():S170-7. PubMed ID: 16231051
[TBL] [Abstract][Full Text] [Related]
59. Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.
Simpson GR; Coffin RS
Methods Mol Biol; 2009; 542():551-64. PubMed ID: 19565922
[TBL] [Abstract][Full Text] [Related]
60. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
